AIM Vaccine (HKG:6660) applied for clinical trial approval of its mRNA vaccine for herpes zoster or shingles in the US, according to a Sunday filing with the Hong Kong stock exchange.

The application comes as the vaccine's immune indicators were significantly higher compared with the use of international commercially available recombinant subunit control vaccines, the filing said.

There is still no mRNA shingles jab approved for marketing worldwide, the filing said.